Haimanti Dorai

Senior Research Fellow at Centocor - , N/A, US

Haimanti Dorai's Colleagues at Centocor
Eleanor Seeds

Sr. Clinical Project Scientist

Contact Eleanor Seeds

Eric Beil

Associate Scientist II

Contact Eric Beil

Helene Hill

Project Mgmt Specialist

Contact Helene Hill

Chad Daly

Sr. Manager Medical Education (Johnson & Johnson)

Contact Chad Daly

Christine Lammers

Senior Executive Immunology Specialist-

Contact Christine Lammers

View All Haimanti Dorai's Colleagues
Haimanti Dorai's Contact Details
HQ
610-651-6000
Location
Philadelphia, Pennsylvania, United States
Company
Centocor
Haimanti Dorai's Company Details
Centocor logo, Centocor contact details

Centocor

, N/A, US • 1000 - 4999 Employees
BioTech/Drugs

Subsidiary of Johnson & Johnson, Centocor is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic assays using monoclonal antibody technology.In 1982 Centocor developed their first product approved by the U.S. Food and Drug Administration (FDA) — a diagnostic test used to detect the rabies virus, and in that same year transitioned into a publicly traded company. Subsequently, the company moved to a larger facility in Malvern, Pennsylvania (a northwest suburb of Philadelphia). In 1984, Centocor opened an overseas plant in Leiden, the Netherlands.Eighteen years after its foundation, (in 1997), Centocor achieved its first year of operating profitability. In 1998, Centocor divested itself of its diagnostic division and launched its top-selling monoclonal antibody Remicade (infliximab) for its first FDA approved indication in Crohn's Disease. In 1999, Centocor became a wholly owned subsidiary of Johnson & Johnson, the worldwide manufacturer and marketer of healthcare products. Subsequently, Remicade's market has expanded with approvals for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and pediatric Crohn's disease. Remicade was approved for plaque psoriasis in September 2006.Centocor also markets ReoPro (abciximab), a biologic agent indicated as an adjunct to coronary angioplasty (PTCA).Since being acquired by Johnson and Johnson, Centocor has increased its annual sales from approximately $500 million to more than $2 billion. During the same period, research and development investment increased from $75 million to more than $300 million.In 2004 Centocor purchased a new manufacturing plant in St. Louis, Missouri, and is currently opening a new manufacturing facility in County Cork, Ireland. The Dutch plant has been expanded substantially with a $250 million investment in additional production facilities, which were opened in 2006.

BioTech/Drugs Commercial Physical Research Biotechnology
Details about Centocor
Frequently Asked Questions about Haimanti Dorai
Haimanti Dorai currently works for Centocor.
Haimanti Dorai's role at Centocor is Senior Research Fellow.
Haimanti Dorai's email address is ***@centocor.com. To view Haimanti Dorai's full email address, please signup to ConnectPlex.
Haimanti Dorai works in the BioTech/Drugs industry.
Haimanti Dorai's colleagues at Centocor are Eleanor Seeds, Eric Beil, Helene Hill, Michelle Harner, Chad Daly, Kimberly Fields, Christine Lammers and others.
Haimanti Dorai's phone number is 610-651-6000
See more information about Haimanti Dorai